- PMV Pharmaceuticals reported updated interim data from its Phase 2 PYNNACLE clinical trial for rezatapopt, showing a **34% overall response rate (ORR)** among **103 evaluable patients** across all cohorts, with a median duration of response of **7.6 months**.  **[1699382_79e5b22ef5ac40719225244ef3e80e28_0]** **[1699382_79e5b22ef5ac40719225244ef3e80e28_1]** 
- In the ovarian cancer cohort, rezatapopt achieved a **46% ORR** among **48 evaluable patients**, with a median duration of response of **8.0 months**.  **[1699382_79e5b22ef5ac40719225244ef3e80e28_0]** **[1699382_79e5b22ef5ac40719225244ef3e80e28_1]** 
- The company plans to submit a New Drug Application (NDA) for rezatapopt for platinum-resistant/refractory ovarian cancer in the **first quarter of 2027**.  **[1699382_79e5b22ef5ac40719225244ef3e80e28_0]** **[1699382_79e5b22ef5ac40719225244ef3e80e28_2]** 
- Treatment-related adverse events were mostly Grade 1-2, with a drug discontinuation rate of **3.6%** due to TRAEs.  **[1699382_79e5b22ef5ac40719225244ef3e80e28_1]**

PMV Pharmaceuticals (PMVP)